TCI Bio
Native name | 大江生醫股份有限公司 |
|---|---|
| Company type | Public (Taiwan OTC) |
| TWSE: 8436[1] | |
| Industry | Biotechnology; health & personal care manufacturing (CDMO/ODM) |
| Founded | August 1, 1980 |
| Founder | Ta Chiang International Co., Ltd. (original corporate entity) |
| Headquarters | 8F, No. 187, Gangqian Road, Neihu District, , |
Key people | Lin Yong-Hsiang (林詠翔) (Chairman & CEO) |
| Products | Functional beverages, dietary supplements, probiotics, collagen, skincare/beauty products (CDMO/ODM) |
| Revenue | (see financials section) |
Number of employees | ~884 (group-wide, 2021 est.) |
| Website | www |
TCI Co., Ltd. (Chinese: 大江生醫股份有限公司) is a Taiwanese contract development and manufacturing organization (CDMO) specialising in the research, development and production of functional beverages, dietary supplements and skincare products.[2] Headquartered in the Neihu Technology Park in Taipei, TCI evolved from an original trading company founded in 1980 into a CDMO group serving clients across Asia, Europe and North America, and is publicly traded on Taiwan's over-the-counter market under the code 8436.[3]
History
[edit | edit source]The corporate origins trace back to 1980, when the predecessor trading company (Ta Chiang International) was established. In the late 1990s the group created a biomedical division and moved progressively into health-care product development and manufacturing.[4]
In 2011 the company transitioned its business model from an ODM (original design manufacturer) to a CDMO (contract development and manufacturing organisation), emphasising integrated bioscience design, proprietary ingredient development and turnkey manufacturing services for clients seeking private-label and brand products.[5]
The firm went public on Taiwan’s OTC market in 2013 (listing date 12 September 2013) with stock code 8436, accelerating capital access for factory expansion, R&D laboratories and overseas business development.[6]
Since the 2010s TCI has expanded into multiple subsidiaries and business lines (including genetic testing and digital health services), pursued international client partnerships, and invested in laboratory and production capacity—reporting a group workforce in the high hundreds and multiple manufacturing sites and laboratories by the early 2020s.[7]
Operations and products
[edit | edit source]TCI provides end-to-end services for the nutraceutical and cosmetic sectors: market analysis and concept design, ingredient sourcing and proprietary raw material development (IBD—Integrated Bioscience Design), formulation R&D, stability and safety testing, pilot production, and full-scale manufacturing for capsules, softgels, liquids, powders, and cosmetic formulations. The company markets private-label products under group consumer channels as well as acting as a CDMO for domestic and international brands.[8]
Subsidiaries and affiliated brands include genetic testing (TCI GENE) and consumer retail channels (TCI Living), reflecting a diversification strategy across upstream R&D and downstream retail.[9]
Public listing, financials and governance
[edit | edit source]TCI is listed on Taiwan’s OTC market (stock code 8436). Regulatory and investor pages report the company’s registration details, public offering timeline (public offering 25 August 2011; OTC listing 12 September 2013), paid-in capital and disclosure contacts. Quarterly and annual reports are published on the company’s investor relations pages.[10][11]
Recognition and sustainability
[edit | edit source]TCI has publicly promoted sustainability initiatives and in recent years participated in corporate sustainability networks. Industry reporting and chamber notices noted TCI’s membership in RE100 initiatives or climate/sustainability collaborations, positioning the company among early adopters in Taiwan’s biotech/manufacturing sector to commit to renewable energy targets and net-zero ambitions.[12]
Contemporary developments and strategy
[edit | edit source]Throughout the 2020s TCI pursued an acquisition and expansion phase, increasing capacity for CDMO services, establishing additional labs, and extending product portfolios into probiotics, collagen, functional drinks and clinical-grade ingredients.[13] The company emphasizes integrated R&D, regulatory compliance for international markets, and sustainability in manufacturing operations.[14]
Criticism and market challenges
[edit | edit source]As with many contract manufacturers in the nutraceutical and cosmetic sectors, TCI faces sector-wide pressures including regulatory compliance across multiple jurisdictions, supply-chain volatility (raw material sourcing), increasing competition from lower-cost regional producers, and the need to demonstrate product efficacy and safety through independent clinical evidence.[15] Publicly available sources emphasize the company’s efforts to address these through expanded testing capabilities and R&D investment; independent media coverage and financial reports remain the primary sources for external assessment of performance and governance.[16]
See also
[edit | edit source]- Nutraceutical
- Contract development and manufacturing organization
- List of companies of Taiwan
- Daiken Bio
References
[edit | edit source]- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
